Olusoji Akanwo, PHARMACIST in Anza, CA - Pharmacist

Olusoji Akanwo, PHARMACIST is a Pharmacist based in Anza, California. Olusoji Akanwo is licensed to practice in California (license number 46882) and his current practice location is 56555 Hwy 371, Anza, California. He can be reached at his office (for appointments etc.) via phone at (951) 763-7670.

NPI number for Olusoji Akanwo is 1730656349 and his current mailing address is Po Box 390415, Anza, California. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1730656349.

Contact Information

	Olusoji Akanwo, PHARMACIST
	56555 Hwy 371, Anza, CA 92539
	(951) 763-7670
	(951) 763-7670

Healthcare Provider's Profile

Full Name	Olusoji Akanwo
Gender	Male
Speciality	Pharmacist
Location	56555 Hwy 371, Anza, California
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1730656349
Provider Enumeration Date: 11/01/2018
Last Update Date: 11/01/2018

Medical Identifiers

Medical identifiers for Olusoji Akanwo such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1730656349	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
183500000X	Pharmacist	46882 (California)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Olusoji Akanwo is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Olusoji Akanwo, PHARMACIST Po Box 390415, Anza, CA 92539-0415 Ph: (951) 763-7670	Olusoji Akanwo, PHARMACIST 56555 Hwy 371, Anza, CA 92539 Ph: (951) 763-7670

News Archive

Ono, Bristol-Myers Squibb partner to develop BMS-936558/ONO-4538 and ORENCIA

Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd., today announced an agreement to expand Bristol-Myers Squibb's territorial rights to develop and commercialize the anti-PD-1 antibody known as BMS-936558/ONO-4538, and to create a strategic alliance for the co-development and co-commercialization of ORENCIA in Japan.

Guidelines on cardiovascular disease prevention in clinical practice launched at EuroPRevent2012

The latest cardiovascular disease (CVD) prevention guidelines have been overhauled to produce a user friendly document with concise messages that awards greater weight than ever before to evidence from clinical trials and observational population studies. The "European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (version 2012)" - were launched at the EuroPRevent2012 meeting in Dublin, Ireland.

‘When it starts getting into your local hospital, it becomes real'

The folding chairs outside the windows appeared late last month, after the maintenance staff at St. James Parish Hospital labeled each window with a patient room number so families and friends could at least see their loved ones battling COVID-19.

Fluoroquinolones can enhance gene-silencing tool

A way to turn off one gene at a time has earned acceptance in biology laboratories over the last decade. Doctors envision the technique, called RNA interference, as a tool to treat a variety of diseases if it can be adapted to humans.

Olusoji Akanwo, PHARMACIST - Pharmacist in Anza, CA